{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:15Z","timestamp":1792090575435,"version":"4.4.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The purpose of this review is to describe the existing limited data related to the use of semaglutide in adolescents with obesity, supplementing with findings from adult studies of semaglutide use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Semaglutide, as a once weekly subcutaneous injection for weight management, effectively reduces body mass index (BMI) while improving hyperglycemia, elevated alanine aminotransferase levels, hyperlipidemia, and quality of life in youth with obesity. As of this review, only one large randomized clinical trial of semaglutide in youth has been completed, with a follow-up duration of 68\u200aweeks. Thus, long-term data on the safety in adolescents is limited, particularly regarding the risks of cholelithiasis, pancreatitis, suicidal ideation, and disordered eating. Due to the cost of semaglutide, particularly in the United States, limited cost effectiveness analyses have demonstrated unfavorable incremental cost-effectiveness ratios for semaglutide relative to phentermine-topiramate as an alternative antiobesity medication in adolescents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Semaglutide represents an important advance in the pediatric obesity management, with clear short-term reductions in BMI and improvement in metabolic parameters. However, its long-term safety and efficacy for youth with obesity remain to be demonstrated. Additional research is needed to assess trends in utilization and adherence to minimize the risk of worsening socioeconomic disparities in pediatric obesity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001365","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T04:00:58Z","timestamp":1716350458000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice"],"prefix":"10.1097","volume":"36","author":[{"given":"Megan O.","family":"Bensignor","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes, Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota; Division of Pediatric Endocrinology and Diabetes, University of Minnesota Medical School, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Arslanian","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Diabetes, and Metabolism and Center for Pediatric Research in Obesity and Metabolism, UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Vajravelu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Diabetes, and Metabolism and Center for Pediatric Research in Obesity and Metabolism, UPMC Children's Hospital of Pittsburgh and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/dci22-0046","article-title":"Youth-onset type 2 diabetes: the epidemiology of an awakening epidemic","volume":"46","author":"Perng","year":"2023","journal-title":"Diabetes Care"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"e2777","DOI":"10.1210\/clinem\/dgac209","article-title":"Changes in type 2 diabetes trends in children and adolescents during the COVID-19 pandemic","volume":"107","author":"Schmitt","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2337\/dc15-1649","article-title":"Expanding treatment options for youth with type 2 diabetes: current problems and proposed solutions: a White Paper From the NICHD Diabetes Working Group","volume":"39","author":"Tamborlane","year":"2016","journal-title":"Diabetes Care"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and Nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu Rev Med"},{"issue":"(Suppl 1)","key":"R8-20250730","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"(Suppl 3)","key":"R10-20250730","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/oby.22378","article-title":"Obesity as a disease: the Obesity Society 2018 Position Statement","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/oby.23808","article-title":"Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4\u200amg","volume":"31","author":"Kelly","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jpeds.2013.04.003","article-title":"Threshold for improvement in insulin sensitivity with adolescent weight loss","volume":"163","author":"Abrams","year":"2013","journal-title":"J Pediatr"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u200amg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"1170881","DOI":"10.3389\/fendo.2023.1170881","article-title":"Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.3748\/wjg.v29.i37.5327","article-title":"Efficacy and safety of semaglutide in nonalcoholic fatty liver disease","volume":"29","author":"Zhu","year":"2023","journal-title":"World J Gastroenterol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.dsx.2023.102849","article-title":"Role of semaglutide in the treatment of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"17","author":"Bandyopadhyay","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MEG.0000000000002463","article-title":"Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"35","author":"Kovalic","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74\u200amg once weekly in patients with nonalcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/biomedicines11051362","article-title":"Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes","volume":"11","author":"Patti","year":"2023","journal-title":"Biomedicines"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"Eur Psychiatry"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.obpill.2023.100080","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obes Pillars"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"113967","DOI":"10.1016\/j.physbeh.2022.113967","article-title":"Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity","volume":"257","author":"Nicolau","year":"2022","journal-title":"Physiol Behav"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.3390\/ijerph20176638","article-title":"Disordered eating and eating disorders in pediatric obesity: assessment and next steps","volume":"20","author":"Chaves","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamapediatrics.2022.5848","article-title":"Global proportion of disordered eating in children and adolescents: a systematic review and meta-analysis","volume":"177","author":"Lopez-Gil","year":"2023","journal-title":"JAMA Pediatr"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc10-1704","article-title":"Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study","volume":"34","author":"Wilfley","year":"2011","journal-title":"Diabetes Care"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12519-021-00485-2","article-title":"Prevalence of depression and anxiety among children with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Akbarizadeh","year":"2022","journal-title":"World J Pediatr"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/dc11-0431","article-title":"Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study","volume":"34","author":"Anderson","year":"2011","journal-title":"Diabetes Care"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3928\/00485713-20120806-09","article-title":"The relationship between obesity and depression among adolescents","volume":"42","author":"Nemiary","year":"2012","journal-title":"Psychiatr Ann"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"e2336400","DOI":"10.1001\/jamanetworkopen.2023.36400","article-title":"Cost-effectiveness of antiobesity drugs for adolescents with severe obesity","volume":"6","author":"Mital","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"e2329178","DOI":"10.1001\/jamanetworkopen.2023.29178","article-title":"Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents","volume":"6","author":"Lim","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"e2329422","DOI":"10.1001\/jamanetworkopen.2023.29422","article-title":"Interpreting cost-effectiveness analyses of anti-obesity medications for the treatment of adolescent obesity-reading the tea leaves","volume":"6","author":"Wright","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"186","DOI":"10.15585\/mmwr.mm6706a3","article-title":"Prevalence of obesity among youths by household income and education level of head of household \u2013 United States","volume":"67","author":"Ogden","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jama.2020.14590","article-title":"Trends in obesity prevalence by race and Hispanic origin-1999\u20132000 to 2017\u20132018","volume":"324","author":"Ogden","year":"2020","journal-title":"JAMA"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"e13103","DOI":"10.1111\/ijpo.13103","article-title":"Projected impact of anti-obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity","volume":"19","author":"Vajravelu","year":"2024","journal-title":"Pediatric Obes"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/dtb.2023.000007","article-title":"Semaglutide: a new drug for the treatment of obesity","volume":"61","author":"Lexchin","year":"2023","journal-title":"Drug Ther Bull"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A Randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:07:10Z","timestamp":1753898830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001365","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]}}}